1. Introduction {#sec1}
===============

Spindle cell carcinoma (SpCC) is an uncommon subtype of squamous cell carcinoma. Morphologically, it is a biphasic tumor consisting of a squamous cell carcinoma in situ and/or invasively and a malignant spindle cell component with a mesenchymal phenotype \[[@B1]\]. Due to the heterogeneous and complex nature of the tumor, it was reported under various terms such as carcinosarcoma, sarcomatoid carcinoma, collision tumor, pleomorphic carcinoma, and pseudosarcoma. The improvements in our understanding of monoclonal epithelial origin of these tumors finally led to the proposal of using the term "spindle cell carcinoma" \[[@B2]\].

SpCC is observed mainly in the larynx, especially in the glottic region. Its incidence is 0.023 per 100,000, and it represents 0.5% of all laryngeal squamous cell carcinomas \[[@B3]\]. The tumor occurs usually as a smooth-surfaced polypoid mass that arises from the true vocal cord and anterior commissure \[[@B4]\]. Although it has an aggressive biological character, the probability of making a diagnosis in the early stages is high as it often leads to obstructive symptoms such as hoarseness, snoring, and coughing in the early period \[[@B5]\]. Due to its low incidence, there is no clear consensus on prognostic factors and optimal treatment strategies yet.

In this paper, a laryngeal SpCC case that was effectively treated with wide local excision followed by adjuvant radiotherapy was presented with the literature.

2. Case Presentation {#sec2}
====================

The present study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Akdeniz University School of Medicine (Antalya, Turkey). Written informed consent was obtained from the patient.

A 60-year-old male patient was referred to the Akdeniz University School of Medicine with the complaint of chronic hoarseness that has existed for five years and noticeably increased in the last year. He had a history of 40 pack-years of cigarette smoking. Multiple medications prescribed by several different specialists due to diagnosis of vocal cord nodule failed to improve the symptoms. Although the head and neck examination was unremarkable, endoscopic examination revealed a submucosal nodular lesion with a smooth surface that was located in the middle of the right vocal cord ([Figure 1](#fig1){ref-type="fig"}).

The laryngeal nodule was totally excised for pathological examination under direct laryngoscopy. Microscopic examination of the tumor revealed atypical spindle cells that were dispersed in a desmoplastic stroma under an ulcerated surface epithelium with fibrinoid necrosis and invasive tumor foci of squamous cell carcinoma ([Figure 2](#fig2){ref-type="fig"}). Epithelial component of the tumor exhibited strong immunoreactivity for cytokeratin and p63. Surgical margins were negative for tumor infiltration, but focally close, with tumor less than 2 mm from the posterior margin.

Adjuvant radiotherapy was administered due to close surgical margins while metastatic work-up with positron emission tomography combined with computed tomography was negative for systemic dissemination. The patient is now in the 12th month of his follow-up after a complete clinical response to primary therapy.

3. Discussion {#sec3}
=============

SpCC is an aggressive malignant tumor typically observed in upper aerodigestive tract, in which nearly half of the cases are of larynx origin \[[@B6]\]. It was first reported in the literature in 1933 by Figi, under the name of "larynx sarcoma" \[[@B7]\]. According to recent population-based analysis data, a total of 312 cases of laryngeal SpCC were diagnosed in the United States of America between 1973 and 2011 \[[@B3]\].

Macroscopically, the tumor mostly has a polypoid appearance but may rarely occur as an infiltrative ulcerative lesion \[[@B1]\]. It is diagnosed by histologically showing the combination of a malignant mesenchymal spindle cell component that can contain homologous or heterologous elements and a surface squamous cell component that includes dysplasia, carcinoma in situ, or invasive carcinoma \[[@B1]\]. Epithelial and mesenchymal components can be present either separately or in a nested form while the spindle cell component usually constitutes the larger part of the tumor \[[@B8]\].

The heterogeneous morphological structure of SpCC poses significant diagnostic difficulties. The pathological differential diagnosis includes squamous cell carcinoma, leiomyosarcoma, fibrosarcoma, rhabdomyosarcoma, malignant melanoma, and inflammatory myofibroblastic tumor \[[@B9]\]. The biopsy samples that are taken superficially or in small pieces can lead to missing one of the components of the biphasic tumor and therefore misdiagnosis of SpCC as squamous cell carcinoma or sarcoma. In some cases, the differential diagnosis may not be possible even with the totally resected specimens without immunohistochemistry.

The cytokeratin, which has been reported to be expressed in 40--85% of the cases, is the most sensitive immunohistochemical marker that shows the epithelial component of the SpCC \[[@B5]\]. Epithelial membrane antigen (EMA) and carcinoembryonic antigen are other epithelial markers that exhibit variable immunoreactivity in these tumors \[[@B9]\]. Mesenchymal component of the SpCC frequently exhibits positive immunostaining with vimentin, which is also an epithelial marker \[[@B1]\]. Such a staining pattern supports the idea that these tumors are of epithelial origin and the sarcomatous spindle cells occur as a result of mesenchymal metaplasia \[[@B2]\]. Immunostaining with vimentin may also be positive for leiomyosarcomas. However, leiomyosarcoma cells show negative immunoreactivity for cytokeratins and positive immunoreactivity for muscle-specific actin \[[@B9]\].

Immunohistochemical studies usually allow reliable discrimination of SpCCs and sarcomas. On the other hand, it may lead to ambiguous results in some cases where the tumor lacks specific immunoreactivity. In such cases, the p63, which is a transcription factor of epidermal stem cell origin, can be beneficial in the discrimination of SpCCs from sarcomas. In a study assessing the diagnostic utility of several immunohistochemical markers of epithelial differentiation including p63, MOC-31, and thyroid transcription factor-1 on SpCCs, Lewis Jr. et al. \[[@B10]\] reported that staining for p63 had the greatest diagnostic utility. While immunostaining with p63 was positive in 63% of SpCCs, it was negative in the control group of 73 various primary and metastatic sarcomas, melanomas, and benign spindle cell lesions. The p63 stains were positive in many cases where immunohistochemistry was negative for both pan-cytokeratin and EMA.

Electron microscopy is another diagnostic tool used in the differential diagnosis of SpCCs with sarcomas \[[@B11], [@B12]\]. Although its use has declined significantly with the use of immunohistochemical stains, it may still have a role in tumors with inconclusive staining pattern. While the SpCCs have the combined epithelial and myofibroblastic features of desmosomes, tonofibrils, and filaments with dense bodies, fibrosarcomas consist largely of fibroblastic cells and leiomyosarcomas are packed in forming small cell groups with constant junctional complexes of nexus and zonula adherens types \[[@B12]\].

Ruling out a laryngeal mesenchymal malignancy is of critical importance in the differential diagnosis of SpCCs, since these tumors have a different histogenesis, natural history, biological behavior, and prognosis. Dubal et al. \[[@B3]\] reported that the majority of laryngeal SpCC cases have T1 (62%) and stage I (61%) tumors at presentation. Lymph node metastasis may occur (12.6%) but distant metastasis is uncommon (3.7%). The surgery yields a favorable prognosis when compared to radiotherapy. The 5-year disease-specific survival (DSS) is 84.0% with surgery alone, 84.2% with surgery combined with radiotherapy, and 60.5% with radiotherapy alone (*P* \< 0.012). In addition, a glottic location of the tumor, as opposed to a nonglottic location, is significantly associated with improved prognosis (5-year DSS, 84.0% versus 51.9%, *P* \< 0.0001). Compared to other laryngeal malignancies, SpCCs have intermediate (5-year) survival benefit (74.1% versus 64.6%, *P* \< 0.020), but short-term (1-year, 90.9% versus 88%) and long-term (10-year, 57.9% versus 50.6%) survival rates are similar. Likewise, Thompson et al. \[[@B5]\] reported that a wide local excision should be the treatment of choice in most SpCC patients as these tumors are mostly of polypoid or pedicular nature and do not invade the stroma especially in the early period. The authors also suggested that radiotherapy might be used in the existence of recurrence or stromal invasion. On the other hand, in a retrospective study assessing the outcomes of early-stage (T1-T2) glottic SpCC cases (*n* = 28) treated with primary radiotherapy, Ballo et al. \[[@B13]\] reported that these patients had similar local-control rates to irradiated patients with similar volume disease with the more typical squamous cell carcinoma. Therefore, the authors suggested that the histologic diagnosis of SpCC instead of squamous cell carcinoma should not alter treatment recommendations in patients with early-stage disease.

In conclusion, laryngeal SpCC is an unusual occurrence that can be mostly diagnosed in the early stages despite its aggressive histological features. A wide local excision alone is mostly sufficient for definitive treatment in the early-stage disease. Adjuvant radiotherapy may be beneficial in local control of the disease in patients with close surgical margins.
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